CAS: 55294-15-0; 5-Amino-2-(1-(3,4-Dichlorophenyl)Ethyl)-2,4-Dihydro-3H-Pyrazol-3-One

该化合物是一种循环二尿素,其化学结构来自pyrazinoylguanidine, 其作用是抑制Na+-K+-2Cl-2Cl-2Symporter在Henle环绕的厚厚的上方, 推广二尿素和氮尿素. 与其他循环二尿素相比, Muzolimine 表现出了长期的动作, 因为它独特的药理动因特征, 包括消化速度较慢. 特别值得注意的是, 它在管理与通血性心脏衰竭和肾脏损伤有关的水肿方面的效力. 化合物表现出可耐性, 治疗剂量的电解不平衡风险降低. 它独特的药理特性使得它在需要持续电素效应的临床环境中成为有价值的选择.

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      📜[1-(3,4-二氯苯基)乙基]肼,β-Amino-β-Ethoxyacrylic Acid Ethyl Ester 以51%的收率获得产物
      参考文献:
      标题:

      海关参考信息

      专利信息


      专利号:US-10925977-B2
      优先权日:2006-10-05
      标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
      发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
      权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
      摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

      专利号:US-2008287407-A1
      优先权日:2003-12-10
      标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
      发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
      权利人:NITROMED INC
      摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

      专利号:US-12295961-B2
      优先权日:2009-12-31
      标 题:Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
      发明人:DHINGRA OM
      权利人:MARIUS PHARMACEUTICALS INC
      摘要:A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

      专利号:EP-0180707-A1
      优先权日:1984-10-04
      标题:Process for the preparation of muzolimine
      发明人:NAAB PAUL DR; ERTEL WERNER DR
      权利人:BAYER AG
      摘要:Improved process for the synthesis of 1-substituted 3-amino-5-pyrazolones, in which in a first step a hydrazine derivative is condensed with alkyl beta -amino- beta -alkoxyacrylate under acidic conditions and the intermediate is subjected in a second step to a ring closure reaction in strongly basic medium at temperatures below 10 DEG C.

      专利号:US-11617758-B2
      优先权日:2009-12-31
      标 题 :Emulsion formulations
      发明人:DHINGRA OM; BERNSTEIN JAMES S
      权利人:MARIUS PHARMACEUTICALS LLC
      摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

      专利号:US-2013303495-A1
      优先权日:2009-12-31
      标题:Emulsion formulations
      发明人:DHINGRA OM; BERNSTEIN JAMES S
      权利人:SOV THERAPEUTICS; DIFFERENTIAL DRUG DEV ASSOCIATES LLC
      摘要:A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Grima M, Michel B, Barthelmebs M, Stephan D, Imbs JL. The effects of muzolimine and urine from muzolimine-treated rats on Na+K+Cl- cotransport in Madin-Darby canine kidney cells. Eur J Pharmacol. 1991 Sep 17;202(2):137-42. Italian. German. Italian. Italian. French.

      合成参考文献


      参考文献:10.1023/a:1007835821228
      摘要:Reyes AJ, Taylor SH. Diuretics in cardiovascular therapy: the new clinicopharmacological bases that matter. Cardiovasc Drugs Ther. 1999 Sep;13(5):371–98. doi: 10.1023/a:1007835821228.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知